All In Biotech

Drug Trial Radar · NCT04676373

Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen

A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatment

Last checked: Nov 20, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

41

Actual

Start

Mar 10, 2021

Primary completion

Jul 25, 2024

Study completion Jul 25, 2024

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Dec 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate the effect of one-year Alglucosidase alfa treatment on motor function \[Six-minute walk test (6MWT) and lung function predicted Forced vital capacity (FVC)\] among Chinese Late Onset Pompe Disease patients above 5 years old. To evaluate the safety of Myozyme 20mg/kg, IV biweekly in Chinese LOPD patients above 3 years old. Secondary Objective: To evaluate the effect of one-year treatment with Alglucosidase alfa on improvement of manual muscle test (MMT), Maximal inspiratory and expiratory pressure (MIP and MEP)\], Quick Motor Function Test scores, and health-related quality of life (SF-12) among LOPD patients over 5 years old.

Conditions

  • Pompe's Disease

Interventions

  • ALGLUCOSIDASE ALFADrug

    Pharmaceutical form:solution for infusion Route of administration: intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Six-minute walk test (6MWT) for the patients ≥5-year oldTime frame: Baseline to 12 months
  2. Change from baseline in percent predicted forced vital capacity (%FVC) in upright position for the patients ≥5-year oldTime frame: Baseline to 12 months
  3. Number of participants with adverse events Number of AEsTime frame: From signing the ICF to the 30th day after the last dosage of the study medications

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational Site

    China, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.